3S Pharma

What 3S Pharma does

3S Pharma (legally 3S – Pharmacological Consultation & Research GmbH) is a privately held, full-service Contract Research Organization (CRO) headquartered in Wildeshausen, Germany, that has operated for more than 25 years (founded 1995). The company provides end-to-end clinical research services to pharmaceutical and biotechnology clients, spanning Phase I-IV studies, First-in-Human (FIH) trials, bioequivalence/bioavailability (BA/BE) studies, drug-drug interaction analyses, pharmacokinetic profiling, transdermal drug delivery system (TDDS/TDS) development and validation, and clinical monitoring and auditing. Clinical operations are conducted through units in Romania (via subsidiary Pharma Serv International in Bucharest) and Moldova, with a state-of-the-art bioanalytical laboratory using HPLC-MS/MS and LBA technologies that processes over 100,000 samples annually.

The company has cumulatively managed more than 1,500 registered clinical studies on behalf of partner companies. Its operations have passed inspections by the US FDA (2023), the EMA (2024), and multiple European national agencies including ANSM (France), BfArM (Germany), AGES (Austria), CCMO (The Netherlands), DKMA (Denmark), and ANMDMR (Romania), confirming ICH-GCP compliance. Additional service offerings include a data collection service for machine learning applications and a fast-track regulatory approval pathway via Moldova enabling approvals in as little as 2 weeks.

The business model is professional services / project-based, with quote-based, customized pricing per study and direct enterprise sales engagement with pharma and biotech clients. There is no public disclosure of revenue, headcount trends, funding history, ownership structure, or named customer accounts in the available data, which represents a meaningful information gap for investment-grade assessment. The company markets itself as offering cost-efficient, personalized study design without compromising quality, regulatory compliance, or safety.

Name

3S Pharma

Legal name

3S – Pharmacological Consultation & Research GmbH

Website

https://3spharma.eu

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

3S Pharma is a privately held German full-service Contract Research Organization (CRO) providing Phase I-IV clinical trials, bioanalytical laboratory services, transdermal patch development, and pharmacokinetic studies to pharmaceutical and biotechnology clients, operating clinical units in Romania and Moldova with FDA- and EMA-validated compliance.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

Keywords

• Contract research organization
• Clinical trial services
• Bioanalytical laboratory services
• Pharmacokinetic studies
• Bioequivalence studies

Headquarters

HQ city

Harpstedt

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Research Services: Full-service CRO offering end-to-end clinical research services including Phase I-IV studies, bioequivalence/bioavailability studies, pharmacokinetic studies, and post-clinical surveillance. Revenue generated through project-based contracts with pharmaceutical and biotech companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

3S Pharma is a full-service Contract Research Organization (CRO) providing end-to-end clinical development and bioanalytical services. The company conducts Phase I-IV clinical trials, bioequivalence and bioavailability studies, First-in-Human studies, pharmacokinetic profiling, and transdermal patch development, supported by a state-of-the-art bioanalytical laboratory using HPLC-MS/MS and LBA technologies. It serves pharmaceutical and biotech companies with operations in clinical research units in Romania and Moldova, validated by FDA (2023) and EMA (2024) inspections.

Product overview

3S Pharma is a full-service Contract Research Organization (CRO) providing end-to-end clinical research solutions. The portfolio includes clinical research studies across all phases (Phase 1-4), a state-of-the-art bioanalytical laboratory (HPLC-MS/MS and LBA technologies), transdermal patch development and validation (TDDS/TDS), pharmacokinetic studies, and clinical monitoring and auditing services. Additional offerings include AI/ML-enabled data collection for clinical research and fast track regulatory approval services. The company operates clinical research units in Romania and Moldova, serving global pharmaceutical development programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Research Studies Comprehensive clinical trial services spanning Phase 1 through Phase 4 studies, including First-in-Human (FIH) studies, bioequivalence/bioavailability (BA/BE) studies, drug-drug interaction studies, pharmacokinetic profiles, adhesion performance studies, and pain assessment studies. Targeted at pharmaceutical and biotech companies requiring outsourced clinical development.
• Bioanalytical Laboratory Services State-of-the-art bioanalytical laboratory processing over 100,000 samples annually using HPLC-MS/MS and LBA (Ligand Binding Assay) technologies to generate robust biomarker data for product development and validation. Serves pharmaceutical and biotech companies requiring biomarker analysis and product validation.
• Transdermal Patches (TDDS/TDS) Development and Validation Development and validation of transdermal drug delivery systems (TDDS/TDS) including adhesion and performance testing to ensure optimal drug delivery through transdermal patches. Targeted at pharmaceutical companies developing transdermal drug products.
• Pharmacokinetic Studies Comprehensive pharmacokinetic studies evaluating how drugs are absorbed, distributed, metabolized, and excreted, including drug-drug interaction analysis. Targeted at pharmaceutical and biotech companies requiring PK profiling and drug-drug interaction assessments.
• Clinical Monitoring & Auditing Services Clinical monitoring and auditing services ensuring data integrity, regulatory compliance, and study reliability throughout all clinical phases. Serves pharmaceutical and biotech companies requiring compliance assurance across clinical trial programs.
• Data Collection for Machine Learning Specialized data collection services enabling AI-enhanced clinical research, including analysis of patient responses under stress conditions, blood glucose fluctuations, and liver function variations. Targeted at organizations requiring AI/ML-ready clinical datasets.
• Fast Track Regulatory Approvals Accelerated regulatory pathway navigation services enabling clinical trial approvals in as little as 2 weeks, particularly through Moldova fast track programs. Targeted at pharmaceutical and biotech companies needing rapid study startup.

Quantifiable outcome

• 100,000+ samples processed annually in bioanalytical laboratory
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medpace: Mid-to-large global CRO operating across Phases I-IV with strong bioanalytical and clinical operations. Direct competitor for early-phase and BA/BE work, but with a much larger, global footprint and broader therapeutic range than 3S Pharma.
• Syneos Health: Large clinical and commercial CRO services provider covering Phase I-IV and bioanalytical adjacent services. Competes with 3S Pharma for biotech and pharma early- and late-phase mandates.
• Charles River Laboratories: Large CRO/biopharma services company with overlapping early-phase clinical, bioanalytical, and discovery services. Competes for similar biotech/pharma clients on Phase I and PK studies.
• Parexel International: Global full-service CRO offering Phase I-IV, clinical logistics, and bioanalytical services. Direct competitor on early-phase and bioequivalence mandates that 3S Pharma services.
• PRA Health Sciences (now part of ICON): Large full-service global CRO offering Phase I-IV, bioanalytical labs, and clinical monitoring. Direct overlap on 3S Pharma's core CRO services, with much broader geographic and operational scale.
• IQVIA: World's largest CRO and clinical research services provider; competes for any Phase I-IV, bioanalytical, or pharmacovigilance mandate that 3S Pharma pursues, at a vastly larger scale.

Direct peers

• Bioskin (now Clinsys/Calyx Clinical Research Services): European early-phase CRO with strong German footprint and Phase I / bioanalytical capabilities; tightly overlaps with 3S Pharma in BA/BE, PK, and FIH studies for European pharma clients.
• Worldwide Clinical Trials: Mid-size clinical CRO with notable early-phase and bioanalytical capabilities, overlapping directly with 3S Pharma's Phase I, BA/BE, and PK service lines for pharma/biotech sponsors.
• Ergomed (now part of Asahi Kasei): Mid-size CRO with strong pharmacovigilance, Phase I-IV, and bioanalytical offerings. Closely comparable to 3S Pharma in service mix and sponsor type, especially in European markets.

Emerging players

• Anteris Clinical Research: Smaller specialty CRO focused on early-phase and complex clinical pharmacology, similar in scale and niche to 3S Pharma, serving pharma/biotech sponsors needing FIH, BA/BE, and PK studies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/3spharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3S Pharma